472 related articles for article (PubMed ID: 24602176)
1. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm.
Choi HS; Lee SY; Kim JH; Sung IK; Park HS; Shim CS; Jin CJ
J Dig Dis; 2014 Jun; 15(6):293-8. PubMed ID: 24602176
[TBL] [Abstract][Full Text] [Related]
2. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
Ghoshal UC; Kumar S; Krishnani N; Kumari N; Chourasia D; Tripathi S
Trop Gastroenterol; 2011; 32(4):292-8. PubMed ID: 22696910
[TBL] [Abstract][Full Text] [Related]
3. The new modified ABCD method for gastric neoplasm screening.
Park CH; Kim EH; Jung DH; Chung H; Park JC; Shin SK; Lee SK; Lee YC
Gastric Cancer; 2016 Jan; 19(1):128-35. PubMed ID: 25663259
[TBL] [Abstract][Full Text] [Related]
4. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies.
Cao Q; Ran ZH; Xiao SD
J Dig Dis; 2007 Feb; 8(1):15-22. PubMed ID: 17261130
[TBL] [Abstract][Full Text] [Related]
5. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
Yoshida T; Kato J; Inoue I; Yoshimura N; Deguchi H; Mukoubayashi C; Oka M; Watanabe M; Enomoto S; Niwa T; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Takeshita T; Ushijima T; Ichinose M
Int J Cancer; 2014 Mar; 134(6):1445-57. PubMed ID: 24009139
[TBL] [Abstract][Full Text] [Related]
6. Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm.
Boda T; Ito M; Yoshihara M; Kitamura Y; Matsuo T; Oka S; Tanaka S; Chayama K
Helicobacter; 2014 Feb; 19(1):1-8. PubMed ID: 24215601
[TBL] [Abstract][Full Text] [Related]
7. Relationship between Helicobacter pylori status and serum pepsinogens as serologic markers in atrophic gastritis.
Bölükbaş C; Bölükbaş FF; Ovünç O; Kiliç G; Dalay R; Güven H; Uras F; Yardimci TK; Sökmen MH; Agan AF; Pişkinpaşa N
Turk J Gastroenterol; 2006 Sep; 17(3):172-6. PubMed ID: 16941249
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia.
Leja M; Cine E; Rudzite D; Vilkoite I; Huttunen T; Daugule I; Rumba-Rozenfelde I; Pimanov S; Liepniece-Karele I; Pahomova J; Purmalis K; Eglitis J; Pirags V; Dzerve V; Erglis A
Eur J Gastroenterol Hepatol; 2012 Dec; 24(12):1410-7. PubMed ID: 23114744
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study.
Kiso M; Yoshihara M; Ito M; Inoue K; Kato K; Nakajima S; Mabe K; Kobayashi M; Uemura N; Yada T; Oka M; Kawai T; Boda T; Kotachi T; Masuda K; Tanaka S; Chayama K
Gastric Cancer; 2017 Sep; 20(5):764-771. PubMed ID: 28025702
[TBL] [Abstract][Full Text] [Related]
10. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status.
Hansen S; Vollset SE; Derakhshan MH; Fyfe V; Melby KK; Aase S; Jellum E; McColl KE
Gut; 2007 Jul; 56(7):918-25. PubMed ID: 17317788
[TBL] [Abstract][Full Text] [Related]
11. Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis.
Watanabe M; Kato J; Inoue I; Yoshimura N; Yoshida T; Mukoubayashi C; Deguchi H; Enomoto S; Ueda K; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Tekeshita T; Mohara O; Ushijima T; Ichinose M
Int J Cancer; 2012 Dec; 131(11):2632-42. PubMed ID: 22383377
[TBL] [Abstract][Full Text] [Related]
12. Response of IgG1 and IgG2 subclasses to Helicobacter pylori in subjects with chronic inflammation of the gastric mucosa, atrophy and gastric cancer in a country with high Helicobacter pylori infection prevalence.
Vorobjova T; Ren Z; Dunkley M; Clancy R; Maaroos HI; Labotkin R; Kull K; Uibo R
APMIS; 2006 May; 114(5):372-80. PubMed ID: 16725014
[TBL] [Abstract][Full Text] [Related]
13. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study.
Sasazuki S; Inoue M; Iwasaki M; Otani T; Yamamoto S; Ikeda S; Hanaoka T; Tsugane S;
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1341-7. PubMed ID: 16835334
[TBL] [Abstract][Full Text] [Related]
14. Serum pepsinogen levels in gastric cancer patients and their relationship with Helicobacter pylori infection: a prospective study.
So JB; Yeoh KG; Moochala S; Chachlani N; Ho J; Wong WK; Mack P; Goh PM
Gastric Cancer; 2002; 5(4):228-32. PubMed ID: 12491081
[TBL] [Abstract][Full Text] [Related]
15. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer.
Pimanov SI; Makarenko EV; Voropaeva AV; Matveenko ME; Voropaev EV
J Gastroenterol Hepatol; 2008 Nov; 23(11):1666-71. PubMed ID: 17559360
[TBL] [Abstract][Full Text] [Related]
16. Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio--a possible novel and non-invasive marker for gastric atrophy.
Suzuki H; Masaoka T; Hosoda H; Nomura S; Ohara T; Kangawa K; Ishii H; Hibi T
Hepatogastroenterology; 2004; 51(59):1249-54. PubMed ID: 15362725
[TBL] [Abstract][Full Text] [Related]
17. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels.
Yanaoka K; Oka M; Yoshimura N; Mukoubayashi C; Enomoto S; Iguchi M; Magari H; Utsunomiya H; Tamai H; Arii K; Yamamichi N; Fujishiro M; Takeshita T; Mohara O; Ichinose M
Int J Cancer; 2008 Aug; 123(4):917-26. PubMed ID: 18508314
[TBL] [Abstract][Full Text] [Related]
18. Helicobacter pylori antibodies in relation to precancerous gastric lesions in a high-risk Chinese population.
Zhang L; Blot WJ; You WC; Chang YS; Kneller RW; Jin ML; Li JY; Zhao L; Liu WD; Zhang JS; Ma JL; Samloff IM; Correa P; Blaser MJ; Xu GW; Fraumeni JF
Cancer Epidemiol Biomarkers Prev; 1996 Aug; 5(8):627-30. PubMed ID: 8824365
[TBL] [Abstract][Full Text] [Related]
19. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels.
Yanaoka K; Oka M; Ohata H; Yoshimura N; Deguchi H; Mukoubayashi C; Enomoto S; Inoue I; Iguchi M; Maekita T; Ueda K; Utsunomiya H; Tamai H; Fujishiro M; Iwane M; Takeshita T; Mohara O; Ichinose M
Int J Cancer; 2009 Dec; 125(11):2697-703. PubMed ID: 19610064
[TBL] [Abstract][Full Text] [Related]
20. Helicobacter pylori, pepsinogen, and gastric adenocarcinoma in Hawaii.
Nomura AM; Kolonel LN; Miki K; Stemmermann GN; Wilkens LR; Goodman MT; Perez-Perez GI; Blaser MJ
J Infect Dis; 2005 Jun; 191(12):2075-81. PubMed ID: 15897993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
